Overview
Semaglutide is contraindicated in MTC, MEN 2, pregnancy, breastfeeding. Boxed warning: thyroid C-cell tumors (rodent studies, human relevance unknown).
Related clinical pages
- STEP trial results
- SELECT trial results
- FLOW trial results
- Mechanism of action
- Dosing & pharmacology
- Contraindications
- Side effects
Key facts, checked November 20, 2026
The Wegovy label lists two contraindications: a personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN 2), and a prior serious allergic reaction to semaglutide or any ingredient. The Wegovy label lists a boxed warning about thyroid C-cell tumors in rodents and warnings for pancreatitis, gallbladder disease, low blood sugar, kidney injury, allergic reactions, diabetic eye complications, faster heart rate and suicidal thoughts. The Zepbound and Saxenda labels carry the same thyroid boxed warning. Before any GLP-1 prescription, a clinician should ask about these histories; a telehealth intake that does not ask is a red flag. Compounded products have no FDA label of their own, as FDA’s page on unapproved GLP-1 drugs notes.